Table 3.
Characteristics of DRs and RECIST v1.1 defined CR + PR + SD before and after PSM
| Characteristics n (%) | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| RECIST v1.1 defined CR + PR + SD N = 84 | DRs N = 52 | p value | RECIST v1.1 defined CR + PR + SD N = 40 | DRs N = 40 | p value | |
| Age [mean (SD)] | 58.82 (9.44) | 56.98 (11.10) | 0.304 | 56.83 (10.21) | 57.63 (10.99) | 0.737 |
| Sex | ||||||
| Male | 66 (78.6) | 41 (78.8) | 0.970 | 32 (80.0) | 31 (77.5) | 0.785 |
| Female | 18 (21.4) | 11 (21.2) | 8 (20.0) | 9 (22.5) | ||
| Histology | ||||||
| Adenocarcinoma | 45 (53.6) | 31 (59.6) | 0.324 | 23 (57.5) | 22 (55.0) | 0.866 |
| Squamous-cell carcinoma | 25 (29.8) | 17 (32.7) | 12 (30.0) | 14 (35.0) | ||
| Other | 14 (16.7) | 4 (7.7) | 5 (12.5) | 4 (10.0) | ||
| Treatment | ||||||
| PD-1 | 76 (90.5) | 50 (96.2) | 0.317 | 40 (100.0) | 38 (95.0) | 0.494 |
| PD-L1 | 8 (9.5) | 2 (3.8) | 0 (0.00) | 2 (5.0) | ||
| Combined chemotherapy | ||||||
| Yes | 24 (28.6) | 19 (36.5) | 0.332 | 13 (32.5) | 17 (42.5) | 0.356 |
| No | 60 (71.4) | 33 (63.5) | 27 (67.5) | 23 (57.5) | ||
| Number of prior therapy | ||||||
| 0 | 48 (57.1) | 19 (36.5) | 0.020 | 14 (35.0) | 16 (40.0) | 0.644 |
| ≥ 1 | 36 (42.9) | 33 (63.5) | 26 (65.0) | 24 (60.0) | ||
| PD-L1 expression [mean (SD)] | 43.44 (25.30) | 32.12 (25.39) | 0.012 | 35.90 (21.37) | 35.93 (27.07) | 0.996 |
| Stage | ||||||
| III | 17 (20.2) | 6 (11.5) | 0.188 | 8 (20.0) | 5 (12.5) | 0.363 |
| IV | 67 (79.8) | 46 (88.5) | 32 (80.0) | 35 (87.5) | ||
| Combined immunotherapy | ||||||
| Yes | 1 (5.0) | 0 (0.00) | 1.000 | 0 (0.00) | 0 (0.00) | 1.000 |
| No | 19 (95.0) | 32 (100.0) | 17 (100.0) | 17 (100.0) | ||
| Dosage of ICIs | ||||||
| Standard | 80 (95.2) | 49 (94.2) | 1.000 | 37 (92.5) | 38 (95.0) | 1.000 |
| Nonstandard | 4 (4.8) | 3 (5.8) | 3 (7.5) | 2 (5) | ||